We are excited to announce the latest event in our
Asthma & COPD series, which returns to London on the 11th-12th April 2018.
With asthma and chronic obstructive pulmonary disorder (
COPD) affecting about 500 million people worldwide, opportunities in drug development are vast and reducing serious attacks by improving adherence could save $19 billion a year in U.S. healthcare costs
Recent advances in injectable biologics and smart medical devices as led to an increase in novel approaches to treating severe
asthma and COPD as well as the regulations to take into consideration. As technology soars, the need for guideline updates from regulators has increased and continues to be modified.
Join us as we discuss current clinical trials and the innovative digital technology being used to improve clinical adherence. Leading industry experts will be looking at the use of 'real world data' human factors in the design of medical devices and triple combination treatments on the market. We will also be looking at
asthma and COPD Phenotyping and biomarker application and differences between in the EU and US for the approval of biologics. We will be exploring the complexities of dry powder formulation and helping you determine clinical efficacy and endpoints.
Topics for 2018:
- Early detection and prevention of COPD and Asthma
- The use of triple combination therapies
- Health economics and market access for innovative treatments
- Regulatory updates in bioequivalence and drug-device combinations
- Enhancing dry powder formulation
- Asthma and COPD Phenotyping and biomarker application for personalised medicines
Plus One Interactive Half-Day Pre-Conference Workshop | Tuesday 10th April 2018
Paradigm Shift in the Design of Generic Drug-Device Combination productsWorkshop Leader: Dr Suresh Gupta, Head of Human Factors and Usability Engineering, UK, Cambridge Consultants
13.30 - 17.00
Speakers
- Alison Moore, Clinical Development Manager , GSK
- Chris Corrigan, Professor of Asthma, Allergy and Immunology, Kings College London
- Christopher Stevenson, Venture Leader, COPD Interception, Janssen
- David Leather, Medical Vice President, Global Respiratory Franchise, GSK
- Fred Wong, Head and Associate Professor, Department of Pharmacology, National University of Singapore
- Georg Brauers, Senior Manager Regulatory Affairs, Boehringer Ingelheim GmbH
- grzegorz Woszczek, Principal Investigator, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, King’s College London
- Jaquie Finn, Head of Digital Health , Cambridge Consultants Ltd
- Jonathan Phillips, Principal Scientist, Inflammation, Amgen
- Maria Gerhardsson de Verdier, Principal Scientist, Director Epidemiology, AstraZeneca
- Peter Barnes, Professor of Thoracic Medicine and Head of Respiratory Medicine , National Heart & Lung Institute
- Phillip Monk, Chief Scientific Officer , Synairgen Ltd
- Quan Yang, Pharmaceutical Assessor, MHRA
- Rene van der Merwe, Director Clinical Development, Respiratory and Inflammation, MedImmune
- Richard Costello, Professor, Royal College Of Surgeons In Ireland
- Tim Higenbottam, Senior Pharmaceutical Pysician, Allergy Therapeutics
- Wisia Wedzicha, Professor of Respiratory Medicine and Head of Respiratory Clinical Science, Imperial College London
- Yassine Amrani, Principal Investigator , NIHR Biomedical Research Centre
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
Who should attend:
Directors, principle scientists, senior scientists, associate directors, managing directors, medical directors, pharmaceutical experts, group leaders, inhalation toxicologists of the following departments:
- clinical pharmacology
- respiratory medicine/ science
- respiratory immunology
- pulmonary specialty
- respiratory physiology
Venue
Copthorne Tara HotelScarsdale Place, Kensington
London, United Kingdom
